Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

149 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.
Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Savic RM, et al. Among authors: Nsubuga P. Version 2. Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2. Clin Pharmacol Ther. 2017. PMID: 28124478 Free PMC article. Clinical Trial.
Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration.
Pekovic V, Mayanja H, Vjecha M, Johnson J, Okwera A, Nsubuga P, Mugerwa R, Ellner J, Whalen C. Pekovic V, et al. Among authors: Nsubuga P. J Clin Epidemiol. 1998 Jul;51(7):597-607. doi: 10.1016/s0895-4356(98)00033-x. J Clin Epidemiol. 1998. PMID: 9674667 Clinical Trial.
Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda.
Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, Michael NL, Mugerwa RD, Ellner JJ. Whalen CC, et al. Among authors: Nsubuga P. AIDS. 2000 Jun 16;14(9):1219-28. doi: 10.1097/00002030-200006160-00020. AIDS. 2000. PMID: 10894287 Free PMC article.
For subjects with a CD4 lymphocyte count > 200 x 10(6)/l, the 1-year survival proportion was slightly lower in the cases than in the controls (0.91 versus 0.96), but by 2 years the survival proportion was significantly lower in the cases than in the controls (0.84 versus 0.91; P < 0.02; log-rank test). For subjects with a CD4 lymphocyte count of 200 x 10(6) cells/l or fewer, the survival proportion at 1 year for the controls was lower than cases (0.59 versus 0.64), but this difference was not statistically significant (P = 0.53; logrank test). ...
For subjects with a CD4 lymphocyte count > 200 x 10(6)/l, the 1-year survival proportion was slightly lower in the cases than in the cont …
Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.
Johnson JL, Okwera A, Nsubuga P, Nakibali JG, Whalen CC, Hom D, Cave MD, Yang ZH, Mugerwa RD, Ellner JJ. Johnson JL, et al. Among authors: Nsubuga P. Int J Tuberc Lung Dis. 2000 Nov;4(11):1032-40. Int J Tuberc Lung Dis. 2000. PMID: 11092715 Free PMC article.
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults.
Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugyenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC; Uganda-Case Western Reserve University Research Collaboration. Johnson JL, et al. Among authors: Nsubuga P. AIDS. 2001 Nov 9;15(16):2137-47. doi: 10.1097/00002030-200111090-00009. AIDS. 2001. PMID: 11684933 Clinical Trial.
Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.
Okwera A, Johnson JL, Luzze H, Nsubuga P, Kayanja H, Cohn DL, Nunn P, Ellner JJ, Whalen CC, Mugerwa RD. Okwera A, et al. Among authors: Nsubuga P. Int J Tuberc Lung Dis. 2006 Jan;10(1):39-44. Int J Tuberc Lung Dis. 2006. PMID: 16466035 Free PMC article.
The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/100 PYO (P = 0.0001) in patients treated with 2 EHRZ/4HR or 2EHRZ/6HR, respectively. ...
The relapse rate was 18.2 per 100 person-years observation (PYO) for the study regimen compared to 9.7/100 PYO (P = 0.0063) and 4.8/1 …
Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment.
Lamunu D, Chapman KN, Nsubuga P, Muzanyi G, Mulumba Y, Mugerwa MA, Goldberg S, Bozeman L, Engle M, Saukkonen J, Mastranunzio S, Mayanja-Kizza H, Johnson JL. Lamunu D, et al. Among authors: Nsubuga P. Int J Tuberc Lung Dis. 2012 Apr;16(4):480-5. doi: 10.5588/ijtld.11.0434. Int J Tuberc Lung Dis. 2012. PMID: 22640513 Free PMC article. Clinical Trial.
149 results
Jump to page
Feedback